Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention: From the FU-Registry

Nagata, I; Ike, Amane; Nishikawa, Hiroaki; Zhang, Bo; Sugihara, Makoto; Mori, Ken; Iwata, Atsushi; Kawamura, Akira; Shirai, Kohji; Uehara, Yoshio; Ogawa, Masahiro; Miura, Shin‐ichiro; Saku, Keijiro

doi:10.1016/j.jjcc.2014.03.016

Cited by 10 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, whether statin use has a beneficial effect on clinical outcomes in the HD population has been controversial and the debate is ongoing regarding the ideal LDL cholesterol level. From these points, the findings of the article by Nagata et al [4] are concurring with the previous reports.…”

supporting

confidence: 86%

“…In this issue of the Journal of Cardiology, Nagata et al [4] report that low-density lipoprotein (LDL) cholesterol levels could not predict major adverse cardiac events in HD patients undergoing PCI. It is well known that lipid profiles greatly affect clinical outcome in non-HD populations [5].…”

mentioning

confidence: 99%

“…A recent post hoc analysis of the 4D study revealed that treatment with atorvastatin significantly reduces cardiac events in HD patients with type 2 diabetes, if they have pretreatment LDL levels >145 mg/dl [7]. Because of the limited number of enrolled patients in the study by Nagata et al [4], further studies should be warranted. Also, the importance of HDL levels should also be investigated.…”

mentioning

confidence: 99%

“…In assessing GNRI, serum albumin levels and body mass index are important factors [12]. Nagata et al [4] also suggested that body mass index independently predicted the incidence of major adverse cardiac events.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Can lipid profiles predict clinical outcomes in hemodialysis patients with ischemic heart disease?

Ishii

Murohara

2015

Journal of Cardiology

View full text Add to dashboard Cite

Can lipid profiles predict clinical outcomes in hemodialysis patients with ischemic heart disease? Needless to say, drug-eluting stents (DESs) significantly reduce the risk of restenosis after percutaneous coronary intervention (PCI). However, effects of DES implantation have been limited in patients on maintenance hemodialysis (HD) [1,2]. Basically, patients with renal impairment, particularly endstage renal disease, frequently have systemic atherosclerosis [3]. One possibility is that higher rates of prevalence of traditional risk factors, such as advanced age, diabetes, and hypertension in the HD population may affect such high cardiovascular events [3].

show abstract

supporting

confidence: 86%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Can lipid profiles predict clinical outcomes in hemodialysis patients with ischemic heart disease?

Ishii

Murohara

2015

Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…In addition, the results show an increase in serum triglycerides levels in patients undergoing hemodialysis compared to healthy subjects. Different studies such as (17,18) confirm the results obtained in this study. The main causes expressed for the increase of triglyceride in chronic dialysis patients are plasma clearance of triglycerides and increased hepatic triglyceride synthesis.…”

Section: Discussionsupporting

confidence: 91%

The Levels of Inflammatory Markers (IL-6, CRP), Homocysteine and Lipid Profile in Hemodialysis Patients, Isfahan

Sabzevari

Shahanipour

Moshtaghie

2019

Hormozgan medical journal

View full text Add to dashboard Cite

Background: Cardiovascular disease (CVD) and inflammation are among the most common causes of mortality in dialysis patients. Factors such as chronic inflammation, dyslipidemia and elevated homocysteine levels may underlie the increased risk of CVD. Objectives: This study aimed to investigate levels of inflammatory markers, homocysteine, lipid profile, WBC, and BMI levels in hemodialysis patients compared with the control subjects in Isfahan. Methods: A total of 32 hemodialysis patients and 32 healthy subjects were selected randomly and their serum levels of IL-6, CRP, homocysteine, and lipid profiles were measured. Results: According to the results, most of the studied hemodialysis patients compared to the healthy subjects had non-normal amounts of IL-6, CRP, and homocysteine i.e., higher than healthy subjects (P < 0.05). Cholesterol, HDL, and LDL were significantly lower than the healthy subjects (P < 0.05), while triglycerides and VLDL levels showed no significant difference (P: 0.38 > 0.05). A significant difference of BMI was observed between the normal subjects and the patients; thus, this factor in patients was less than what was in the healthy group (P: 0.001 < 0.05). Conclusions: The results demonstrated that in most patients the levels of factors IL-6, CRP, and homocysteine were abnormal compared to the healthy group. In addition, the risk of developing cardiovascular and inflammatory disease as well as dyslipidemia in these patients is higher than normal.

show abstract

Successful modeling of long term outcomes in end‐stage renal disease patients undergoing percutaneous coronary intervention with drug‐eluting stents

Dunn

Huded

Raymond

et al. 2021

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives The objective of this study is to identify and model risk factors for major adverse cardiac events (MACE) and all‐cause mortality among patients with ESRD treated with PCI using DES. Background Patients with end‐stage renal disease (ESRD) have poor long‐term outcomes after percutaneous coronary intervention (PCI) compared with non‐ESRD patients. However, there is a paucity of literature regarding risk factors associated with outcomes of ESRD patients after PCI with drug‐eluding stents (DES). Methods This retrospective cohort study includes all patients with ESRD who underwent first‐time PCI with DES at a single, high‐volume hospital between 1/1/2005 and 12/31/2015, with follow‐up through 9/1/2019. Primary outcomes were MACE (cardiac death, myocardial infarction, or unplanned revascularization) and all‐cause mortality. Results Five‐year MACE was 83.0% and five‐year morality was 77.9% in patients with ESRD (n = 285). Among ESRD patients, factors independently associated with MACE were C‐reactive peptide level, SYNTAX score, peripheral vascular occlusive disease, hemoglobin, and treatment of a restenotic lesion (c‐index = 0.66). Factors independently associated with mortality in ESRD patients were age, SYNTAX score, non‐use of statins at baseline, insulin‐dependent diabetes, chronic obstructive pulmonary disease (COPD), peripheral vascular occlusive disease, and platelet count (c‐index = 0.65). Conclusions Despite relatively poor 1‐and 5‐year outcomes among ESRD patients after PCI, risk of MACE and mortality among this cohort can be successfully modelled, which meaningfully informs clinicians regarding management of ESRD patients with coronary artery disease (CAD). Further investigations are necessary to determine whether or not outcomes might be improved through risk profile modification.

show abstract

Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention: From the FU-Registry

Abstract: BMI, CABG, and insulin use, but not LDL-C, are independent predictors of MACE in HD patients, suggesting that the application of lipid management for non-HD patients to HD patients at the time of PCI may not necessarily be beneficial for medium-term clinical outcomes.

Cited by 10 publications

References 35 publications

Can lipid profiles predict clinical outcomes in hemodialysis patients with ischemic heart disease?

Can lipid profiles predict clinical outcomes in hemodialysis patients with ischemic heart disease?

The Levels of Inflammatory Markers (IL-6, CRP), Homocysteine and Lipid Profile in Hemodialysis Patients, Isfahan

Successful modeling of long term outcomes in end‐stage renal disease patients undergoing percutaneous coronary intervention with drug‐eluting stents

Contact Info

Product

Resources

About